Wolfe Research downgraded AbbVie (ABBV) to Peer Perform from Outperform.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Revolution Medicines down 15% in after-hours after AbbVie denies takeover talks
- AbbVie tells Bloomberg not in talks to buy Revolution Medicines
- AbbVie says not in discussions with Revolution Medicines, Reuters reports
- Erasca up 66% after WSJ report on AbbVie interest in Revolution Medicines
- Revolution Medicines extends gain to 29% after resuming trading